What is the 13F Pro Quality Score for USNA?

13F Pro ranks USANA HEALTH SCIENCES INC (USNA) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View USNA's current score at https://13fpro.ai/research/USNA (free sign-up required for the full ranking).

Where does 13F Pro source USNA data?

All USANA HEALTH SCIENCES INC fundamentals and ownership data come directly from SEC EDGAR. USANA HEALTH SCIENCES INC files with the SEC under CIK 896264. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is USNA in?

USANA HEALTH SCIENCES INC (USNA) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is USNA research updated on 13F Pro?

USNA's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

USANA HEALTH SCIENCES INC(USNA)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →NYSE

Institutional-grade research for retail investors

SEC EDGAR: CIK 896264 USNA stock profile & AI dashboard →

13F Pro Quality Score

40.0/100

Rank #1,956 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

36.4/100

Profitability

33.8/100

Balance Sheet

56.1/100

Earnings Quality

6.7/100

Free Cash Flow

41.5/100

Institutional Flow

27.0/100

Revenue Scale

48.4/100

Dilution Risk

47.2/100

USNA Stock Analysis & AI Quality Score

AI stock analysis and institutional research for USANA HEALTH SCIENCES INC (USNA), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores USNA at 40.0/100 on a 32-signal composite quality model, placing it at rank #1,956 of 2,879 stocks — the bottom half of the AI-ranked universe. Areas of concern include earnings quality (6.7) and institutional flow (27.0), which score below median versus the broader universe. Shareholder dilution risk is elevated at 47.2/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), USANA HEALTH SCIENCES INC reports quarterly revenue of $250.2M, net income of $7.5M, an operating margin of 5.5%. Top institutional holders of USNA by reported 13-F value include BlackRock,, PZENA INVESTMENT MANAGEMENT, RENAISSANCE TECHNOLOGIES, based on the most recent SEC filings. USNA trades on the NYSE exchange and files with the SEC under CIK 896264. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate USNA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for USANA HEALTH SCIENCES INC directly from SEC EDGAR. USANA HEALTH SCIENCES INC's 13F Pro composite quality score has ranged between 8 and 61 since 2021, currently 40.0 — a declining long-term trajectory across 56 quarterly and live scoring snapshots.

Revenue

Q1 2026

$250.2M

Net Income

Q1 2026

$7.5M

Free Cash Flow

Q1 2026

$7.1M

Operating Margin

Q1 2026

5.5%

ROIC

Q1 2026

2.5%

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

-7.2% YoY

$854.5MFY 2024

FY21 $1.19BFY22 $998.6MFY23 $921.0MFY24 $854.5M

Net Income

-34.1% YoY

$42.0MFY 2024

FY21 $116.5MFY22 $69.3MFY23 $63.8MFY24 $42.0M

Operating Income

-28.7% YoY

$66.3MFY 2024

FY21 $170.2MFY22 $107.6MFY23 $93.1MFY24 $66.3M

EPS (Diluted)

-33.6% YoY

$2.19FY 2024

FY21 $5.73FY22 $3.59FY23 $3.30FY24 $2.19

Total Assets

+18.2% YoY

$748.2MFY 2024

FY21 $577.7MFY22 $596.5MFY23 $632.8MFY24 $748.2M

Op. Cash Flow

-13.7% YoY

$61.0MFY 2024

FY21 $121.2MFY22 $103.9MFY23 $70.6MFY24 $61.0M

Metric	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2018
Revenue	$854.5M -7.2%	$921.0M -7.8%	$998.6M -15.8%	$1.19B +4.6%	$1.13B -4.6%	$1.19B
Net Income	$42.0M -34.1%	$63.8M -8.0%	$69.3M -40.5%	$116.5M -6.5%	$124.7M -1.2%	$126.2M
Operating Income	$66.3M -28.7%	$93.1M -13.5%	$107.6M -36.8%	$170.2M -3.6%	$176.5M -6.3%	$188.4M
EPS (Diluted)	$2.19 -33.6%	$3.30 -8.1%	$3.59 -37.3%	$5.73 -2.2%	$5.86 +14.5%	$5.12
Total Assets	$748.2M +18.2%	$632.8M +6.1%	$596.5M +3.3%	$577.7M -9.9%	$640.9M +15.6%	$554.5M
Operating Cash Flow	$61.0M -13.7%	$70.6M -32.0%	$103.9M -14.3%	$121.2M -24.4%	$160.4M +5.4%	$152.1M

AI Insight: USNA Financial Trends

USNA revenue stabilized near $230M but profitability remains volatile with inconsistent operating cash flow.

• Revenue rebounded to $250M in Q2 2026 from $226M in Q1 2026, matching Q1 2025 peak.

• Net income swung from -$7M loss in Q3 2025 to $8M profit in Q2 2026, showing recovery.

• Operating cash flow turned negative in Q3 2025 and Q1 2026 before improving to $10M in Q2 2026.

⚠ Operating margin collapsed to -1.4% in Q4 2024 and 0.5% in Q3 2025; stability unproven.

⚠ Operating cash flow volatility — swung from -$2M and -$3M in recent quarters to $10M.

⚠ Equity drifted higher to $544M in Q2 2026; total debt unavailable, limits leverage assessment.

AI Insight: USNA Ratio Trends

USNA's profitability metrics have collapsed to single-digit returns across all measures, signaling structural deterioration from 2024 peaks.

• Operating margin fell from 8.4% in Q2 2024 to 5.5% in Q2 2026; net profit margin compressed from 4.9% to 3.0% over same period.

• ROIC declined from 13.9% in Q2 2024 to 10.2% in Q2 2026; TTM ROIC now stands at 6.6%, below Q2 2024 levels.

• Q3 2024 and Q3 2025 both posted negative margins (-1.6% operating, -3.2% net in Q4 2024; 0.6% and -3.0% in Q3 2025), suggesting seasonal weakness.

⚠ ROE and ROA remain anemic at 5.5% and 4.1% in Q2 2026—below historical cost of equity, indicating value destruction.

⚠ TTM profitability metrics (OpMargin 3.9%, NPM 1.0%, ROIC 6.6%) lag latest quarter Q2 2026, signaling deterioration in earlier TTM quarters.

Get alerted when USNA's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for USANA HEALTH SCIENCES INC including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of USNA

BlackRock, Inc.
$20.8M1,190,416 sh
PZENA INVESTMENT MANAGEMENT LLC
$19.4M1,108,933 sh
RENAISSANCE TECHNOLOGIES LLC
$17.8M1,017,630 sh
DIMENSIONAL FUND ADVISORS LP
$14.6M834,223 sh
Nantahala Capital Management, LLC
$14.2M810,074 sh
VANGUARD CAPITAL MANAGEMENT LLC
$8.4M479,043 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$5.9M338,274 sh
CHARLES SCHWAB INVESTMENT MANAGEMENT INC
$5.8M333,112 sh
AQR CAPITAL MANAGEMENT LLC
$5.2M296,420 sh
GEODE CAPITAL MANAGEMENT, LLC
$4.6M264,434 sh

Fund	Value	Shares
BlackRock, Inc.	$20.8M	1,190,416
PZENA INVESTMENT MANAGEMENT LLC	$19.4M	1,108,933
RENAISSANCE TECHNOLOGIES LLC	$17.8M	1,017,630
DIMENSIONAL FUND ADVISORS LP	$14.6M	834,223
Nantahala Capital Management, LLC	$14.2M	810,074
VANGUARD CAPITAL MANAGEMENT LLC	$8.4M	479,043
VANGUARD PORTFOLIO MANAGEMENT LLC	$5.9M	338,274
CHARLES SCHWAB INVESTMENT MANAGEMENT INC	$5.8M	333,112
AQR CAPITAL MANAGEMENT LLC	$5.2M	296,420
GEODE CAPITAL MANAGEMENT, LLC	$4.6M	264,434

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put USNA on your watchlist

Track score changes the day USANA HEALTH SCIENCES INC files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is USNA a good stock to buy?

13F Pro's AI-powered analysis of USANA HEALTH SCIENCES INC (USNA) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for USNA are available on the USNA stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own USNA?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling USNA. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of USANA HEALTH SCIENCES INC's investment landscape.